Role of endoscopy in predicting the disease course in inflammatory bowel disease

被引:0
作者
Matthieu Allez [1 ]
Marc Lémann [1 ]
机构
[1] Department of Gastroenterology and Equipe AVENIR INSERM,Saint-Louis Hospital,APHP,Université Denis Diderot Paris 7,75010 Paris,France
关键词
Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Colonoscopy; Natural history; Outcome; Medical therapy; Surgery;
D O I
暂无
中图分类号
R574 [肠疾病];
学科分类号
1002 ; 100201 ;
摘要
Endoscopy provides a direct evaluation of mucosal lesions in inflammatory bowel disease(IBD),permitting the description of elementary lesions,their surface extent and severity.The severity of mucosal lesions directly reflects disease activity and may help to identify an aggressive behavior of the disease.Several studies have recently pointed out the potential role of endoscopy in the prediction of IBD outcome.Indeed,severe endoscopic lesions in Crohn’s disease(CD) patients,defined by deep and extensive ulcerations on at least one part of the colon,are associated with an increased risk of penetrating complication and surgery.Severe endoscopic lesions during severe attacks of ulcerative colitis(UC) are associated with an increased risk of colectomy in the short and long term.Severity of postoperative recurrence in CD may help to predict the risk of clinical relapse and need for further surgery.Achievement of mucosal healing,which can be obtained by administration of several types of drugs,is associated with a better outcome,less surgery and hospitalization.This review focuses on the assessment of endoscopic severity in CD and UC and on the impact of endoscopic severity on disease outcome.More specifically,we discuss how endoscopy can be used at different stages of IBD to predict the disease course and/or to adapt treatment strategies.
引用
收藏
页码:2626 / 2632
页数:7
相关论文
共 17 条
[1]   Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease [J].
Baert, Filip ;
Moortgat, Liesbeth ;
Van Assche, Gert ;
Caenepeel, Philip ;
Vergauwe, Philippe ;
De Vos, Martine ;
Stokkers, Pieter ;
Hommes, Daniel ;
Rutgeerts, Paul ;
Vermeire, Severine ;
D'Haens, Geert .
GASTROENTEROLOGY, 2010, 138 (02) :463-468
[2]   Importance of Mucosal Healing in Ulcerative Colitis [J].
Lichtenstein, Gary R. ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (02) :338-346
[3]   Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab [J].
Sandborn, William J. ;
Rutgeerts, Paul ;
Feagan, Brian G. ;
Reinisch, Walter ;
Olson, Allan ;
Johanns, Jewel ;
Lu, Jiandong ;
Horgan, Kevin ;
Rachmilewitz, Daniel ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
de Villiers, Willem J. S. ;
Present, Daniel ;
Sands, Bruce E. ;
Colombel, Jean Frederic .
GASTROENTEROLOGY, 2009, 137 (04) :1250-1260
[4]  
961 Infliximab Discontinuation in Crohn’s Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study[J] . Edouard Louis,Gwenola Vernier-Massouille,Jean-Charles Grimaud,Yoram Bouhnik,David Laharie,Jean-Louis Dupas,Hélène Pillant,Laurence Picon,Michel Veyrac,Mathurin Flamant,Guillaume Savoye,Raymond Jian,Martine De Vos,Gilles Paintaud,Eric Piver,Jean-Frederic Colombel,Jean-Yves Mary,Marc Lemann.Gastroenterology . 2009 (5)
[5]   Long-term outcome after infliximab for refractory ulcerative colitis [J].
Ferrante, Marc ;
Vermeire, Severine ;
Fidder, Herma ;
Schnitzler, Fabian ;
Noman, Maja ;
Van Assche, Gert ;
De Hertogh, Gert ;
Hoffman, Ilse ;
D'Hoore, Andre ;
Van Steen, Kristel ;
Geboes, Karel ;
Penninckx, Freddy ;
Rutgeerts, Paul .
JOURNAL OF CROHNS & COLITIS, 2008, 2 (03) :219-225
[6]  
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial[J] . Geert D’Haens,Filip Baert,Gert van Assche,Philip Caenepeel,Philippe Vergauwe,Hans Tuynman,Martine De Vos,Sander van Deventer,Larry Stitt,Allan Donner,Severine Vermeire,Frank J Van De Mierop,Jean-Charles R Coche,Janneke van der Woude,Thomas Ochsenkühn,Ad A van Bodegraven,Philippe P Van Hootegem,Guy L Lambrecht,Fazia Mana,Paul Rutgeerts,Brian G Feagan,Daniel H
[7]  
Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial[J] . Stephen B Hanauer,William J Sandborn,Christian Dallaire,André Archambault,Bruce Yacyshyn,Chyon Yeh,Nancy Smith-Hall.Canadian Journal of Gastroenterology . 2007 (12)
[8]  
A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine[J] . Marc Lémann,Jean-Yves Mary,Jean-Frédéric Colombel,Bernard Duclos,Jean-Claude Soule,Eric Lerebours,Robert Modigliani,Yoram Bouhnik.Gastroenterology . 2005 (7)
[9]  
Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD[J] . Marco Daperno,Geert D’Haens,Gert Van Assche,Filip Baert,Philippe Bulois,Vincent Maunoury,Raffaello Sostegni,Rodolfo Rocca,Angelo Pera,Annemie Gevers,Jean-Yves Mary,Jean-Frédéric Colombel,Paul Rutgeerts.Gastrointestinal Endoscopy . 2004 (4)
[10]   Endoscopy in inflammatory bowel diseases [J].
Hommes, DW ;
Van Deventer, SJH .
GASTROENTEROLOGY, 2004, 126 (06) :1561-1573